June 21, 2018

Chasing the Next Biotech Unicorn

How private equity sets to thrive in the biotech boom in Hong Kong

New listing rules in Hong Kong for biotech and the healthcare reform in China are propelling capital raising activities in the region. Rocketed valuation in the biotech sector drives interest from private equity investments, who demand swift investment cycle with a clear profit-making path for going public. The importance of rigorous and timely pre-investment screening and due diligence process is at an all-time high.

Download this whitepaper to examine the potential opportunities and headwinds in the biotech state-of-play, as well as factors that would drive deal success.

Fill out the form to download this whitepaper.

You may also like:

Datasite Forecaster September Global Outlook

We've all seen the M&A numbers on publicly announced deals. But what's going on beneath the surface? Take a look at our latest report, based on aggregated and anonymized global M&A deal activity on Datasite's platform.

M & A Professional Holding an Umbrella
Deal Drivers: APAC HY 2022

M&A activity across APAC has proven remarkably resilient in the first half of 2022 despite strong headwinds. Read our latest report to learn more about the regions and sectors that drove dealmaking in H1 2022, including the latest heat chart, league tables, and top bidders by value and volume.

Deal Drivers: AMERS HY 2022

Although overall M&A activity has slowed in 2022, the slight deceleration is a mean reversion after an unsustainably busy period. In Deal Drivers: Americas HY 2022 we bring you the highlights and insights from the first half of 2022.

Overhead view of San Francisco